A1c vs Serum Glucose

Hemoglobin A1c (A1c, HbA1c) measures the percentage of hemoglobin that has been glycated — irreversibly modified by glucose attachment. Because glycation accumulates over the lifespan of red blood cells (approximately 120 days), A1c reflects average blood glucose over the preceding 2–3 months, with the most recent 30 days contributing approximately 50% of the result.

A1c does not measure current glucose. It does not detect hypoglycemic episodes. It does not reflect glucose variability — a patient with frequent swings between hypoglycemia and hyperglycemia may have the same A1c as a patient with stable, well-controlled glucose. And it does not capture postprandial glucose spikes, which can be significant contributors to cardiovascular risk even when fasting glucose and A1c appear controlled.

The estimated average glucose (eAG) is a conversion of A1c to an average glucose value in mg/dL: eAG = (28.7 × A1c) − 46.7. An A1c of 7% corresponds to an eAG of approximately 154 mg/dL; an A1c of 8% corresponds to approximately 183 mg/dL. This conversion helps patients understand what their A1c means in terms they recognize from their glucose meter.

A1c is measured by several laboratory methods (HPLC, immunoassay, capillary electrophoresis), and results can vary between methods and laboratories. Standardization through the NGSP (National Glycohemoglobin Standardization Program) has reduced inter-laboratory variability, but clinicians should be aware that A1c values from different laboratories may not be directly comparable.

Any condition that alters red cell lifespan or hemoglobin structure can produce a falsely low or falsely high A1c that does not accurately reflect glycemic control. Recognizing these conditions is essential before making treatment decisions based on A1c.

Conditions that falsely lower A1c (shortened red cell lifespan — less time for glycation to accumulate): hemolytic anemia (any cause), sickle cell disease, recent blood transfusion (donor red cells have not been exposed to the patient's glucose), iron deficiency anemia (accelerated red cell turnover), G6PD deficiency, and chronic kidney disease (uremia causes hemolysis). In these patients, A1c underestimates the true average glucose.

Conditions that falsely elevate A1c (prolonged red cell lifespan — more time for glycation to accumulate): iron deficiency anemia without hemolysis (reduced red cell turnover), splenectomy, and vitamin B12 or folate deficiency. In these patients, A1c overestimates the true average glucose.

Hemoglobin variants (HbS, HbC, HbE) can interfere with some A1c assay methods, producing falsely low or falsely high results depending on the method used. In patients with known hemoglobin variants, the laboratory should be consulted about which assay method is used and whether the result is reliable.

When A1c is unreliable, fructosamine (reflects average glucose over 2–3 weeks) or continuous glucose monitoring (CGM) with time-in-range analysis provides more accurate glycemic assessment. Fructosamine is affected by albumin levels — hypoalbuminemia falsely lowers fructosamine.

The ADA recognizes four diagnostic criteria for diabetes, any one of which is sufficient for diagnosis when confirmed on repeat (or when two different tests are abnormal on the same day): A1c of 6.5% or above, fasting plasma glucose of 126 mg/dL or above (after at least 8 hours of fasting), 2-hour plasma glucose of 200 mg/dL or above during a 75 g oral glucose tolerance test (OGTT), or random plasma glucose of 200 mg/dL or above in a patient with classic symptoms of hyperglycemia.

These tests do not always agree — a patient can meet criteria by one test but not another. This discordance is clinically important. A1c tends to underdiagnose diabetes in populations with conditions that lower A1c (hemolytic anemia, sickle cell disease), and may overdiagnose in populations with conditions that raise A1c. Fasting glucose and OGTT are more sensitive for detecting early glucose dysregulation in some populations.

Prediabetes is defined as: A1c 5.7–6.4%, fasting glucose 100–125 mg/dL (impaired fasting glucose), or 2-hour OGTT glucose 140–199 mg/dL (impaired glucose tolerance). Impaired glucose tolerance (elevated 2-hour OGTT) carries a higher risk of progression to diabetes and cardiovascular disease than impaired fasting glucose alone.

In clinical practice, A1c is the most commonly used diagnostic test because it does not require fasting, is not affected by acute illness or stress, and reflects chronic glycemic exposure. However, in settings where A1c reliability is uncertain (hemoglobinopathy, hemolytic anemia, recent transfusion), fasting glucose or OGTT is preferred.

The ADA recommends an A1c target of less than 7% for most non-pregnant adults with diabetes. This target is associated with reduced risk of microvascular complications (retinopathy, nephropathy, neuropathy) and, over time, reduced cardiovascular risk. However, this is a population-level recommendation — individual targets should be tailored based on patient-specific factors.

Less stringent targets (7.5–8% or even higher) are appropriate for: elderly patients (particularly those above age 75 or with limited life expectancy, where the benefit of tight control does not outweigh the risk of hypoglycemia), patients with frequent or severe hypoglycemia or hypoglycemia unawareness, patients with multiple comorbidities or limited functional status, patients with advanced complications (established cardiovascular disease, CKD stage 4–5, severe neuropathy), and patients for whom the burden of intensive management outweighs the expected benefit.

More stringent targets (6.5% or below) may be appropriate for: younger patients with short disease duration, no significant hypoglycemia risk, long life expectancy, and no established cardiovascular disease — particularly if the target can be achieved without significant hypoglycemia or medication burden.

The ACCORD trial demonstrated that intensive glycemic control (A1c target below 6%) in patients with established cardiovascular disease or high cardiovascular risk was associated with increased mortality — likely due to hypoglycemia. This finding reinforced the importance of individualized targets and the harm of pursuing tight control in high-risk patients.

Continuous glucose monitoring (CGM) provides information that A1c cannot: time-in-range (TIR — percentage of time glucose is between 70–180 mg/dL), time below range (TBR — hypoglycemia), time above range (TAR — hyperglycemia), and glucose variability (coefficient of variation). These metrics capture the full picture of glycemic control that A1c averages away.

Time-in-range above 70% (approximately 17 hours per day between 70–180 mg/dL) is associated with reduced risk of microvascular complications and is the primary CGM-based glycemic target for most patients. Time below range below 4% (less than 1 hour per day below 70 mg/dL) is the hypoglycemia target.

Glucose variability — measured by coefficient of variation (CV) — is an independent risk factor for hypoglycemia and cardiovascular events. A CV above 36% indicates high variability and increased risk, regardless of the A1c value. Two patients with the same A1c can have very different glucose profiles: one with stable, well-controlled glucose and one with wide swings between hypoglycemia and hyperglycemia.

CGM is now recommended for all patients with type 1 diabetes and for patients with type 2 diabetes on insulin or at risk for hypoglycemia. It provides actionable data for medication adjustments, dietary changes, and patient education that A1c alone cannot support.